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-Aminobutyric acid type A (GABAA) receptors, a family of
Cl-permeable ion channels, mediate fast synaptic inhibition as
postsynaptically enriched receptors for -aminobutyric acid at
GABAergic synapses. Here we describe an alternative type of
inhibitionmediatedbyGABAAreceptors present onneocortical
glutamatergic nerve terminals and examine the underlying sig-
naling mechanism(s). By monitoring the activity of the presyn-
aptic CaM kinase II/synapsin I signaling pathway in isolated
nerve terminals, we demonstrate that GABAA receptor activa-
tion correlated with an increase in basal intraterminal [Ca2]i.
Interestingly, this activation of GABAA receptors resulted in a
reduction of subsequent depolarization-evoked Ca2 influx,
which thereby led to an inhibition of glutamate release. To
investigate how the observed GABAA receptor-mediated mod-
ulation operates, we determined the sensitivity of this process to
the Na-K-2Cl cotransporter 1 antagonist bumetanide, as well as
substitution of Ca2 with Ba2, or Ca2/calmodulin inhibition
by W7. All of these treatments abolished the modulation by
GABAA receptors. Application of selective antagonists of volt-
age-gated Ca2 channels (VGCCs) revealed that the GABAA
receptor-mediated modulation of glutamate release required
the specific activity of L- and R-type VGCCs. Crucially, the inhi-
bition of release by these receptors was abolished in terminals
isolated from R-type VGCC knock-out mice. Together, our
results indicate that a functional coupling between nerve termi-
nal GABAA receptors and L- or R-type VGCCs is mediated by
Ca2/calmodulin-dependent signaling. This mechanism pro-
vides aGABA-mediated control of glutamatergic synaptic activ-
ity by a direct inhibition of glutamate release.
GABAA2 receptors, a large and diverse family of Cl-perme-
able ion channels, mediate fast transmission at inhibitory
GABAergic synapses and are critical for the development and
coordination of neuronal activity underlying the majority of
physiological and behavioral processes in the brain (1–3).
GABAA receptors are assembled from seven classes of homol-
ogous subunits, (1–6), (1–3), (1–3), , , , and  (4), into
heteropentamers that display extensive structural and func-
tional heterogeneity at different subcellular localizations (5).
Thus, GABAA receptors also operate as tonically active extra-
synaptic receptors (6–8), and asmodulatory auto- or heterore-
ceptors present on axons and, in some instances, presynaptic
nerve terminals in specific areas of the central nervous system
(9, 10).
Presynaptic inhibition mediated by GABAA receptors was
first described in the spinal cord (11–15). Recent electrophysi-
ological studies have established the presence of presynaptic
GABAA receptors in a number of brain regions, including cer-
ebellum (16–19), hippocampus (20–26), auditory brainstem
(27), ventral tegmental area (28), and others (9). However, from
these studies it is apparent that the presynaptic activity of
GABAA receptors can have diverse effects on properties of neu-
rotransmitter release, ranging from inhibition to stimulation of
spontaneous or evoked release of neurotransmitters, depend-
ing on a type of nerve terminals, brain region, and/or the age of
animals (9). Given that neurotransmitter release results from a
complex cascade of interactions between voltage-gated ion
channels and protein machinery involved in synaptic vesicle
exocytosis, and can be regulated at multiple points in this cas-
cade (29), it is important to establish the exact signaling mech-
anisms activated downstream of GABAA receptors to regulate
this process.
We demonstrate here that GABAA receptors, by regulating
intraterminal calcium concentration ([Ca2]i), increase Ca2/
calmodulin-dependent signaling to inhibit subsequent voltage-
gated Ca2 entry and thereby suppress neurotransmitter
release from glutamatergic terminals isolated from the adult rat
neocortex. We demonstrate further that the inhibition of glu-
tamate release requiresNKCC1 activity, implicating a Cl elec-
trochemical gradient subserving a depolarizing activity of
GABAA receptors in this preparation. Moreover, the modula-
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tion is dependent on the influx of Ca2 via L- or R-typeVGCCs,
although only R-type channels directly contribute to the
release. Themodulatory entry of Ca2 leads to the activation of
calmodulin. Together, our results demonstrate GABAA recep-
tor-mediated and Ca2/calmodulin-dependent down-regula-
tion of VGCCs leading to an inhibition of glutamate release
from nerve terminals.
EXPERIMENTAL PROCEDURES
Preparation of Synaptosomes—Percoll gradient-purified syn-
aptosomes were prepared as described previously (30) from the
cerebral cortices of 2-month-old male Sprague-Dawley rats or
from male wild-type or R-type (CaV2.3) 1E subunit-deficient
(1E/) mutant mice characterized previously (31). On incu-
bation at 37 °C, synaptosomes showmetabolic competence and
ability to release neurotransmitters (32, 33).
Glutamate Release Assay—Synaptosomes (0.1 mg) were
resuspended in 1.5 ml of Hepes-buffered incubation medium
(HBM: 140 mM NaCl, 5 mM NaHCO3, 1 mM MgCl2, 1.2 mM
Na2HPO4, 10 mM glucose, and 20 mM Hepes, pH 7.4), and
placed in an LS-5 spectrofluorimeter (PerkinElmer Life Sci-
ences) at 37 °C with stirring. Glutamate release was assayed in
the presence of glutamate dehydrogenase (50 units/ml, Sigma),
NADP (2 mM), and CaCl2 (1 mM) by on-line fluorimetry, as
described previously (32, 34). Where indicated, synaptosomes
were incubated in the presence of picrotoxin (50–100	M, Toc-
ris), SR 95532 (50 	M, Tocris), strychnine (30 	M, Sigma),
bumetanide (10	M, Sigma),W7 (20	M, Tocris), orW5 (20	M,
Tocris) for 10 min; -agatoxin IVA (100 	M, Alomone Labs),
-conotoxin GVIA (10 	M, Alomone Labs), NiCl2 (50 	M,
Sigma), nifedipine (1	M, Alomone Labs), or SNX-482 (100 nM,
Alomone Labs) for 4 min; and muscimol (10–500 	M, Tocris)
or isoguvacine (10–500	M, Tocris) for 3min prior to the addi-
tion of secretagogue. Other experiments were performed in the
presence of EGTA (0.2 mM) for 7 min, followed by the addition
of either BaCl2 (1mM)with/withoutmuscimol (200	M) or only
muscimol (200	M), and further incubated for 3minprior to the
addition of secretagogue. Release was stimulated as indicated
with 4-aminopyridine (4AP, 1mM), KCl (10mM), or ionomycin
(5	M), 10min after the start of incubation andmonitored at 2-s
intervals. Data were analyzed using Lotus 1-2-3, Microcal Ori-
gin, and Microsoft Excel. Each n indicates the number of indi-
vidual synaptosome preparations used; each preparation was
derived from a single animal. Mean glutamate release S.E. in
the absence or presence of drugs is reported in time course
traces. Unless otherwise indicated, mean release values  S.E.
(nmol/mg protein/5 min) quoted in the text are levels attained
at “steady state” 5 min after stimulation. Additionally, for some
comparisons, the values obtained in the presence of drugs are
expressed as percent of corresponding control values in the
absence of drugs and shown as bar graphs. Statistical analysis
was carried out using one-way ANOVA followed by post-hoc
LSD test. Dose-response curves were fit using a sigmoidal rela-
tionship with variable slope employing GraphPad Prism.
Intraterminal Ca2Measurements—Intraterminal Ca2 lev-
els were assayed by on-line fluorimetry as described previously
(33, 35). Synaptosomes (0.1 mg) were resuspended in 1 ml of
HBMcontaining CaCl2 (0.1mM) and loadedwith Fura 2-AM (5
	M) for 20min at 37 °C. Synaptosomes were washed with HBM
by centrifugation, resuspended in 1.5ml of HBM, and placed in
anLS-5 spectrofluorimeter (PerkinElmer Life Sciences) at 37 °C
with stirring in the presence of CaCl2 (1 mM). Synaptosomes
were incubated for 3 min in the presence of muscimol (10–500
	M) prior to depolarization with 4AP (1 mM). Calibration pro-
cedures were performed as described previously (33). Briefly,
samples were alternately excited at 
  340 nm and 
  380
nm; fluorescence emission was monitored at 
 505 nm, and
fluorescence ratios (excitation 340/380 nm) were calculated.
The maximum fluorescence ratio (i.e. Ca2-saturated Fura-2)
was determined in the presence of 0.1% SDS and the minimum
fluorescence ratio (i.e. Ca2-free Fura-2) in the presence of 20
mM EGTA, added at the end of each experiment. Calculation of
cytosolic [Ca2]iwas carried out assuming aKd value for Fura-2
and Ca2 of 224 nM, using equations as described previously
(36). Cumulative data were analyzed using Lotus 1-2-3.
Changes in intraterminal Ca2 concentration ([Ca2]i), 5min
after the addition of 4AP in the presence of muscimol, were
calculated and expressed as percentage of [Ca2]i measured
under control conditions withoutmuscimol. Statistical analysis
was performed by one-way ANOVA followed by post-hoc LSD
test.
Drug Incubation and Immunoblotting—Synaptosomes were
resuspended in HBM (at 1 mg/ml) in the presence of CaCl2 (1
mM) on ice and placed at 37 °C with stirring to start the incuba-
tion. As indicated in figure legends, synaptosomes were incu-
bated with GABase (0.02–0.4 unit/ml), picrotoxin (1–100 	M),
or bicuculline (10–100 	M) for 10 min or in the presence of
muscimol (10–500 	M) or isoguvacine (1–500 	M) for 2 min
before the lysis with 2% SDS. Protein concentrations were
measured using the BCA assay (Pierce), with bovine serum
albumin as standard. Equal amounts of protein were subjected
to SDS-PAGE and transferred onto nitrocellulose membranes.
Immunoblotting was carried out with a phosphorylation state-
specific antibody that was raised to specifically recognize serine
603(P-site3) insynapsin IphosphorylatedbyCa2/calmodulin-
dependent kinase (CaMK) II (anti-phospho (P)-site 3 synapsin I
antibody, 0.5 	g/ml) or with a total synapsin I antibody (0.5
	g/ml, both kindly provided by Professors P. Greengard and
A. C. Nairn, The Rockefeller University, New York). In addi-
tional immunoblotting experiments, antibodies specific for 1,
2,3,2, and  subunits ofGABAA receptors (kindly provided
by Professor W. Sieghart, Vienna, Austria) were used as
described (37). Primary incubations were followed by incuba-
tion with 125I-labeled protein A (0.05 	Ci/ml; Amersham Bio-
sciences). Blots were exposed to a PhosphorImager screen, and
quantificationof immunoblotswas carried out usingPhosphor-
Imager scanning and ImageQuant software (GE Healthcare).
Values stated are mean changes in phosphorylation (% of con-
trol) S.E.
Immunohistochemistry—Immunofluorescence analysis was
performed on neocortical slices as described previously (38,
39). Sections were incubated with primary antibody solutions
containing anti-P-site 3 synapsin I antibody (0.5 	g/ml), anti-
glutamic acid decarboxylase (GAD) antibody (0.5 	g/ml,
Chemicon), and anti-vesicular glutamate transporter 1
(VGLUT1) antibody (0.2 	g/ml, Chemicon), for 14–16 h at
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4 °C. Sections were then washed (five times for 5 min) in phos-
phate-buffered saline and incubated in phosphate-buffered
saline with 1% bovine serum albumin (w/v) containing a mix-
ture of fluorescently taggedmarkers as follows: goat anti-rabbit
IgG-Alexa 488, goat anti-mouse IgG-Alexa 555, and goat anti-
guinea-pig IgG-Cy5 (all diluted to 1:750; Chemicon). Immuno-
reactivity was visualized using a Zeiss LSM 510 Meta laser-
scanning confocal microscope. The estimation of the
percentage of glutamatergic terminals positive for P-site 3 syn-
apsin I was carried out in six randomly selected areas (324	m2)
in images acquired from neocortical layers I–III, layer IV, and
layers V and VI.
RESULTS
Presynaptic GABAA Receptors Regulate Ca2-dependent
Phosphorylation of Synapsin I in Glutamatergic Nerve
Terminals—To detect the activity of GABAA receptors local-
ized to nerve terminals in the rat neocortex independently from
the large postsynaptic pool of these receptors, we isolated pre-
synaptic nerve terminals (synaptosomes) using a well estab-
lished procedure (30, 40, 41). The presence of GABAA receptor
1, 2, 3, and 2 (short, s and long, l), and the absence of 
subunit, in a highly purified fraction of nerve terminals was
detected by immunoblotting with subunit-specific antibodies
(Fig. 1A, lane S). We hypothesized that the activation of these
receptors may regulate intraterminal Ca2 levels ([Ca2]i) in a
way similar to changes observed in mossy fiber terminals in the
hippocampus (26). To test this hypothesis, we monitored the
effects of GABAA receptor activation or inhibition on the pre-
synaptic CaMKII/synapsin I signaling pathway, using a phos-
phorylation state-specific antibody that recognizes synapsin I
only when phosphorylated by CaMKII at Ser-603 (anti-P-site 3
synapsin I antibody, see Refs. 42, 43). This is a highly sensitive
biochemical reporter of changes in intraterminal [Ca2]i as
synapsin I phosphorylation by CaMKII occurs specifically in
response to depolarization-triggered Ca2 influx, as demon-
strated previously (44). Accordingly, in all synapsin I phospho-
rylation experiments, increases in anti-P-site 3 synapsin I in
response to depolarization (4AP, 1 mM)-triggered Ca2 influx
were monitored as positive controls (Fig. 1, B–F, lanes 4AP).
We first tested whether activation of GABAA receptors with
the agonist muscimol or isoguvacine stimulated CaMKII-de-
pendent signaling in nerve terminals. Immunoblotting with
anti-P-site 3 synapsin I antibody revealed a dose-dependent
FIGURE1.Nerve terminalGABAA receptoractivity regulatesCa
2/calmodulin-dependentphosphorylationof synapsin I.A, immunodetectionofGABAA
receptor subunits in purified neocortical synaptosomes (H, homogenate; P2, crude synaptosomal pellet; S, purified synaptosomes). B and C, dose-dependent
increase in CaMKII-dependent phosphorylation of synapsin I at P-site 3 in the presence of increasing concentrations of muscimol ([Muscimol], 1–500 	M; n
6) (B) and isoguvacine ([Isoguvacine], 1–500	M; n 5) (C).D–F, dose-dependent decrease in CaMKII-dependent phosphorylation of synapsin I at P-site 3 in the
presence of increasing concentrations of GABase ([GABase], 0.02–0.4 unit/ml; n 5) (D) and picrotoxin ([Picrotoxin] 1 	M-100 	M; n 5) (E) and bicuculline
([Bicuculline] 10	M-100	M;n5) (F). Blots (upper panels, B–F) showphospho-site 3-synapsin I (P-site 3 syn) and total synapsin I (syn I). Histograms (lower panels,
B–F) show quantification of changes in synapsin I P-site 3 phosphorylation normalized to controls. Total synapsin I levels were not significantly affected under
any stimulation condition used. *, p 0.05 compared with 100% 37 °C controls (one-way ANOVA with post-hoc LSD test).
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increase in CaMKII-dependent P-site 3 phosphorylation of
synapsin I in the presence of muscimol (1–500 	M), with 500
	M agonist producing a 302.2 68.4% increase compared with
controls (n  6, Fig. 1B, blot P-site 3 syn I and bar graph).
Addition of isoguvacine (1–500 	M) caused a similar dose-de-
pendent stimulation of phosphorylation, with 50 and 500 	M,
respectively, effecting 385.4  132.5 and 670.7  263.7%
increases compared with controls (Fig. 1C, panel P-site 3 syn I
and bar graph). Neither agonist affected the total levels of syn-
apsin I in these experiments (Fig. 1, B and C, panel syn I).
Given the relatively high concentrations of GABAA receptor
agonists required to produce the observed effects, we reasoned
that high affinity GABAA receptors (45)may be tonically active,
because the ambient concentration of GABA in our prepara-
tion has been estimated to be as high as 1–5 	M (at 1 mg/ml
concentration of synaptosomal protein) (46). To reduce the lev-
els of GABA, we incubated synaptosomes with increasing con-
centrations of GABase (a complex of GABA-aminotransferase
and succinic semialdehyde dehydrogenase, 0.02–0.4 unit/ml)
(47). Immunoblotting with anti-P-site 3 synapsin I antibody
revealed a significant dose-dependent decrease in CaMKII-de-
pendent phosphorylation of synapsin I with increasing concen-
trations of GABase (0.02–0.4 unit/ml), reaching 59.8 7.7% of
control in the presence of 0.4 unit/ml (Fig. 1D, panel P-site 3 syn
I and bar graph), without any effect on the total levels of synap-
sin I (Fig. 1D, panel syn I).
To confirm that the observed regulation of presynaptic
CaMKII/synapsin I signaling by ambient GABA was mediated
by GABAA receptors, we incubated synaptosomes with
increasing concentrations of picrotoxin (1–100 	M), a
GABAA receptor Cl channel blocker, or bicuculline (10–
100 	M), a competitive GABAA receptor antagonist. Immu-
noblotting with anti-P-site 3 synapsin I antibody revealed a
dose-dependent decrease in basal levels of CaMKII-dependent
phosphorylation of synapsin I, with statistically significant
effects at 50 	M (63.8  6.8% control) and 100 	M picrotoxin
(61.6 5.8% control, Fig. 1E, panel P-site 3 syn I and bar graph).
Bicuculline produced a significant dose-dependent decrease in
CaMKII-dependent P-site 3 phosphorylation of synapsin I at all
the concentrations tested (10	M, 73.1 8.9%of control; 20	M,
72.4  8.6% control; 50 	M, 55.8  10.3% of control; and 100
	M, 65.0  7.9% control; Fig. 1F, panel P-site 3 syn I and bar
graph). Neither picrotoxin nor bicuculline affected the total
levels of synapsin I (Fig. 1, E and F, panels syn I).
Synapsins are presynaptic proteins expressed ubiquitously in
all presynaptic nerve terminals in the central nervous system
(48). To determine whether the GABAA receptor-mediated
regulation of synapsin I/CaMKII signaling cascade occurs uni-
versally throughout the rat neocortex (layers I–VI) or only in
certain populations of nerve terminals, we carried out triple
labeling immunocytochemistry, followed by confocal micros-
copy and colocalization analysis, using anti-P-site 3 synapsin I
FIGURE 2. Specific localization of CaMKII-phosphorylated synapsin I to
glutamatergic terminals in the rat neocortex. Immunohistochemical char-
acterization of CaMKII-phosphorylated P-site 3-synapsin I (P-SYN, green,
top right), vesicular glutamate transporter (VGLUT1, blue, bottom right) and
glutamic acid decarboxylase (GAD, red, bottom left) in neocortical layers I–III
(A); VI (B); and V–VI (C). Note the colocalization of P-SYNwith VGLUT1 (P-SYN/
VGLUT1, turquoise, top left) but not with GAD, and the mutually exclusive
labeling of GAD and VGLUT1. (Scale bar, 10 	m).
Nerve Terminal GABAA Receptors Regulate Glutamate Release
MARCH 27, 2009•VOLUME 284•NUMBER 13 JOURNAL OF BIOLOGICAL CHEMISTRY 8729













antibody (Fig. 2, A–C, in green),
together with anti-glutamic acid
decarboxylase (GAD) antibody to
identify GABAergic nerve terminals
(Fig. 2, A–C, in red), and anti-
vesicular glutamate transporter
(VGLUT) 1 antibody to identify glu-
tamatergic nerve terminals (Fig. 2,
A–C, in blue). Although terminal-
specific staining was detected with
all three antibodies, P-site 3 synap-
sin I was detected exclusively in a
population of glutamatergic nerve
terminals as reflected by the over-
lapping (green/blue) turquoise color
and evidently absent fromGABAer-
gic terminals (Fig. 2, A–C, merged
images). The quantitative analysis
revealed the presence of P-site 3
synapsin I in 31.1  3.8% (layers
I–III), 19.1  1.7% (layer IV), and
19.2 1.5% (layers V andVI) of glu-
tamatergic nerve terminals in the
neocortex. Complete lack of colo-
calization between GAD and
VGLUT 1 confirmed the specificity
of antibodies used in these experi-
ments. These results, together with
our biochemical experiments, are
indicative of the presence of func-
tional GABAA receptors specifically
on a subset of glutamatergic nerve
terminals in the rat neocortex.
Presynaptic GABAA Receptors
Modulate Glutamate Release
through Control of Depolarization-
dependent Ca2 Influx—To deter-
mine whether presynaptic GABAA
receptor activity regulates gluta-
mate release, synaptosomes (0.1
mg/ml) were incubated in the pres-
ence of increasing doses of musci-
mol (10–500 	M) or isoguvacine
(1–500 	M), followed by the addi-
tion of 1 mM 4AP to trigger release.
Control glutamate release (28.2 
1.6 nmol/mg/5 min) was decreased
in a dose-dependent manner by 200
	M (21.8  1.6 nmol/mg/5 min,
77.2% of control) and 500 	M
(22.6  1.8 nmol/mg/5 min, 80.3%
of control) muscimol (Fig. 3A). Glu-
tamate release (26.9  1.6 nmol/
mg/5min in control) was also inhib-
ited in a dose-dependent manner by
100	M (21.0 1.9 nmol/mg/5min,
80.2% of control), 200 	M (20.5 
1.0 nmol/mg/5 min, 76.3% of con-
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trol), and 500 	M isoguvacine (23.2  1.5 nmol/mg/5 min,
86.2% of control; Fig. 3B). To confirm that the observed inhibi-
tion of 4AP-evoked glutamate release was indeed mediated by
GABAA receptors, we incubated synaptosomeswith 50 and 100
	M picrotoxin (Fig. 3C), or 50 	M SR95531 (Fig. 3D), prior to
the addition of muscimol. The inhibition of control glutamate
release (29.3  0.4 nmol/mg/5 min) by muscimol (200 	M,
24.1  1.3 nmol/mg/5 min, 82.3% of control) was partially
reversed by 50 	M picrotoxin (27.1  0.9 nmol/mg/5 min,
92.7% of the control) and abolished by 100 	M picrotoxin
(29.4  0.8 nmol/mg/5 min, 100.3% of control; Fig. 3C). The
inhibition of control release (26.0  1.3 nmol/mg/5 min) by
muscimol (200 	M, 22  1 nmol/mg/5 min, 84.5% of control)
was also abolished by 50 	M SR95531 (25.6  0.6 nmol/mg/5
min, 98.5% of control; Fig. 3D). However, the inhibition of con-
trol release (24.9 1.4 nmol/mg/5 min) by muscimol (200 	M,
20.7 1.8 nmol/mg/5min, 83.1% of control) was unaffected by
the addition of 30 	M strychnine, a glycine receptor-specific
antagonist (20.1  1.8 nmol/mg/5 min, 80.6% of control; Fig.
3E), further demonstrating a specific role of GABAA receptors
in the observed inhibition of glutamate release. Glutamate
release evoked by 4AP in the absence of extracellular Ca2 was
unaffected by muscimol (200 	M) indicating that GABAA
receptor activity does not influence the release of glutamate
occurring by any reversal of plasma membrane glutamate
transporter (data not shown).
We confirmed theGABAA receptor-mediatedmodulation of
glutamate release using an alternative secretagogue, KCl. Con-
trol glutamate release evoked by 10 mM KCl (19.7 1.3 nmol/
mg/5 min) was potently inhibited by 200 	Mmuscimol (15.0
1.0 nmol/mg/5 min, 76.1% of control; Fig. 3F). Importantly, the
release triggered by Ca2-ionophore ionomycin (5 	M, 8.3 
0.5 nmol/mg/5 min) was unaffected by muscimol (200 	M,
7.8  0.7 nmol/mg/5 min; Fig. 3G). Thus, in stark contrast to
depolarization-dependent release evoked by 4AP or KCl, a
direct increase in [Ca2]iwithout anyVGCCactivationwas not
modulated by GABAA receptor activation. This indicates that
the molecular mechanisms underlying the observed inhibition
of glutamate release by nerve terminal GABAA receptors
involve steps prior to synaptic vesicle recruitment and exocy-
tosis and are likely to operate at the level of voltage-gated ion
channels that trigger glutamate release.
To monitor GABAA receptor-dependent changes in intra-
terminal [Ca2]i directly, we carried out on-line fluorescent
assays using a Ca2-sensitive indicator Fura-2 (36). Although
the application of increasing doses of muscimol caused no
detectable changes in basal [Ca2]i (data not shown), the
depolarization-dependent increase in [Ca2]i ([Ca2]i)
from 155.1 12.2 nM (mean S.E., n 5) to 340.2 nM 39.1
nM (mean  S.E., n  5), under control conditions, was sig-
nificantly attenuated at concentrations of muscimol higher
than 50 	M (Fig. 3H). These data indicate that the ability of
nerve terminals to undergo depolarization-dependent acti-
vation of Ca2 channels is significantly attenuated by prior
GABAA receptor activity.
GABAA Receptor-mediated Inhibition of Glutamate Release
Requires NKCC1 Activity, Influx of Ca2, and Activation of
Calmodulin—To dissect the signaling pathway(s) activated
downstreamofGABAA receptors in glutamatergic nerve termi-
nals, we tested whether the observed regulation of release was
sensitive to the inhibition of the inwardly directed Cl trans-
porter, NKCC1, previously reported to maintain high intrater-
minal [Cl]i in some types of nerve terminals (49, 50). Synap-
tosomes were incubated with bumetanide (10 	M), a selective
NKCC1 inhibitor, and glutamate release was triggered by the
addition of 1mM 4AP (Fig. 4A). Glutamate release of 26.1 0.3
nmol/mg/5 min under control conditions was significantly
decreased to 21.9  0.3 nmol/mg/5 min (83.9% of control) by
muscimol (200 	M). Glutamate release was also significantly
reduced by bumetanide (10 	M) to 16.3 1.8 nmol/mg/5 min
(62.6% of control release). Crucially, muscimol-dependent
inhibition of release was completely abolished in the presence
of bumetanide (15.2 1.0 nmol/mg/5 min; Fig. 4A), indicating
an important role of presynaptic NKCC1 activity, and conse-
quent high intraterminal [Cl]i, in glutamate release and mod-
ulation thereof by presynaptic GABAA receptors.
With a high intraterminal [Cl]i, presynaptic GABAA recep-
tors would be predicted to depolarize glutamatergic nerve ter-
minals and activate voltage-gated Ca2 entry. Although this
increase in Ca2 entry may not be sufficient to trigger vesicle
fusion, it may suffice to instigate the observed modulation of
release by theseGABAA receptors.We tested this hypothesis by
excluding Ca2 during the activation of GABAA receptors, i.e.
by incubating synaptosomes with muscimol in the absence of
FIGURE 3. Nerve terminal GABAA receptor activity inhibits stimulus (4AP)-evoked glutamate release and Ca
2-influx. A and B, 4AP (1 mM)-evoked
glutamate release from synaptosomes incubated in the presence of increasing concentrations of GABAA receptor agonists (in red) muscimol (M, [Musc] (1–500
	M; n 6) (A) and isoguvacine (I, [Isog] 1–500 	M; n 7) (B). Insets show dose-response curves of decreases in 4AP-evoked glutamate release in the presence
of agonists (% control 5 min after 4AP addition). C, 4AP (1 mM)-evoked glutamate release from synaptosomes incubated in the presence of muscimol (M, 200
	M, red) or muscimol and picrotoxin (M/P, 50 	M, dark red; and 100 	M, brown, n  4). Inset quantifies occlusion of muscimol (red)-induced decrease of
4AP-evokedglutamate release (% control 5min after 4AP addition) by picrotoxin (50	M,dark red, and 100	M,brown).D, 4AP (1mM)-evokedglutamate release
from synaptosomes incubated in the presence ofmuscimol (M, 200	M, red) ormuscimol and SR95531 (M/SR, 50	M, dark red, n 4). Inset,quantifies occlusion
ofmuscimol (red)-induced decrease of 4AP-evoked glutamate release (% control 5min after 4AP addition) by SR95531 (50	M, dark red). E, 4AP (1mM)-evoked
glutamate release from synaptosomes incubated in the presence muscimol (M, 200 	M, red) or muscimol and strychnine (M/Str, 50 	M, purple, n 4). Inset
demonstrates the lack of an effect of strychnine (purple) onmuscimol-induced decrease of 4AP-evoked glutamate release (% control 5min after 4AP addition).
F, muscimol (M, 200 	M, red)-induced inhibition of glutamate release triggered by 10 mM KCl (n  5). Inset quantifies the reduction of KCl (10 mM)-evoked
glutamate release by muscimol (red, % control 5 min after KCl addition). G, muscimol (200 	M, red) has no significant effect on ionomycin (5 	M)-induced
glutamate release (n 4). Inset quantifies the effect of muscimol (red) on ionomycin-induced glutamate release (% control 5 min after ionomycin addition).
A–G, glutamate release (mean  S.E., nmol/mg) values were calculated for every 2-s time point, with the cumulative release 5 min after secretagogue
(4AP/KCl/ionomycin) addition used for statistical analysis. *, p  0.05 (one-way ANOVA followed by post-hoc LSD test). H, muscimol-induced decrease in
4AP-evoked change in intraterminal Ca2 concentration (Ca2, increase in 4AP-evoked intraterminal [Ca2] in the presence of muscimol (10–500 	M) is
presented as a percentage of an increase obtained with 4AP in the absence of muscimol). Data points show effects on Ca2 influx obtained 5 min after the
addition of 4AP and represent mean S.E. of five independent experiments. *, p 0.05 (one-way ANOVA followed by post-hoc LSD test).
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extrasynaptic Ca2 prior to trigger-
ing glutamate release by the addi-
tion of 1mM 4AP (in the presence of
1 mM Ca2; Fig. 4B) (51). In these
experiments, although glutamate
release per se (29.1 1.6 nmol/mg/5
min) was not altered, muscimol-de-
pendent inhibition of release was
completely abolished. The release
measured with this protocol was
27.9  1.8 nmol/mg/5 min, similar
to levels obtained in the absence of
muscimol (Fig. 4B). This indicates
an obligate requirement for extra-
synaptosomal Ca2 during the
GABAA receptor-mediated modu-
lation phase. Evidently the modula-
tory pathway needs to be activated
prior to depolarization with 4AP,
given that the presence ofmuscimol
and Ca2 during depolarization as
such (Fig. 4B) is insufficient to pro-
duce an effect. This also implies that
the GABAA receptor-mediated
inhibition of glutamate release is
contingent upon the activation of a
long lastingCa2-dependent signal-
ing mechanism.
We further investigated the sig-
naling role of Ca2 in the observed
GABAA receptor-mediated inhibi-
tion of glutamate release by meas-
uring the effects of muscimol in the
presence of 1 mM BaCl2 instead of
CaCl2. Ba2 is an effective substi-
tute for Ca2 in triggering gluta-
mate release (33) because it can
enter nerve terminals through
VGCCs (52, 53). However, Ba2
does not bind calmodulin and is
therefore ineffective in activating
calmodulin-dependent signaling
pathways (54). Glutamate release
measured in the presence of Ba2
(29.0  0.9 nmol/mg/5 min) was
comparable with the release meas-
ured in the presence ofCa2 (25.6
0.6 nmol/mg/5 min; Fig. 4C),
although slightly increased. How-
ever, the decrease in glutamate
release effected by muscimol (200
	M) seen in the presence of Ca2
(22.5  0.7 nmol/mg/5 min, 87.9%
of control release) was abolished in
the presence of Ba2, i.e. release in
the presence of Ba2/muscimol
(28.1  0.8 nmol/mg/5 min) was
indistinguishable from control
FIGURE 4. GABAA receptor-mediated inhibition of glutamate release requires NKCC1 activity, Ca
2
influx prior to stimulation of release, and calmodulin activation. A, 4AP (1 mM)-evoked glutamate release
from synaptosomes incubated in the presence of 1 mM CaCl2, and in the absence (con, black) or presence of
muscimol (M, 200 	M, red), bumetanide (Bumet, 10 	M, blue), or both (M/Bumet, green). Inset compares
decreases in 4AP-evoked glutamate release by muscimol (red), bumetanide (blue), or muscimol and bumet-
anide (green) as % control release 5 min after 4AP addition (n  4). B, synaptosomes were incubated in the
absence of Ca2 and in the absence (con, black) or presence of muscimol (M, 200 	M, red). The release was
triggered by the addition of 4AP (1mM), immediately followed by the addition of CaCl2 (1mM). Inset compares
4AP-evoked glutamate release in the absence (control) or presence ofmuscimol (red, % control 5min after the
addition of 4AP) when Ca2 is omitted during muscimol treatment (n 3). C, 4AP (1 mM)-evoked glutamate
release from synaptosomes incubated in the presence of CaCl2 (1 mM) and in the absence (con/Ca
2, black) or
presence of muscimol (M/Ca2, red), or in the presence of BaCl2 (1 mM) and in the absence (con/Ba
2, blue) or
presence of muscimol (M/Ba2, green). Inset compares changes in 4AP-evoked glutamate release (% control 5
min after 4AP addition) under the same conditions. Note the lack of the effect of muscimol in the presence of
BaCl2 (n 4).D, 4AP (1mM)-evoked glutamate release from synaptosomes incubated in the presence of 1mM
CaCl2, and in the absence (con,black) or presenceofmuscimol (M, 200	M, red), calmodulin inhibitorW7 (W7, 20
	M, blue), or both (M/W7, green). Inset compares decreases in 4AP-evokedglutamate release bymuscimol (red),
W7 (blue) or muscimol and W7 (green) as % control release 5 min after 4AP addition (n  4). E, 4AP (1 mM)-
evoked glutamate release from synaptosomes incubated in the presence of 1 mM CaCl2, and in the absence
(con, black) or presence of muscimol (M, 200 	M, red), W5 (W5, 20 	M, blue), or both (M/W5, green). Inset
compares decreases in 4AP-evoked glutamate release by muscimol (red), W5 (blue), or muscimol and W5
(green) as % control release 5min after 4AP addition (n 6). Glutamate release (mean S.E., nmol/mg) values
were calculated for every 2-s time point, with the cumulative release 5 min after secretagogue (4AP) addition
being used for statistical analysis. *, p 0.05 (one-way ANOVA with post-hoc LSD test).
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release in the presence of Ba2 (Fig. 4C). These results point to
a key role of Ca2-dependent activation of calmodulin down-
stream of presynaptic GABAA receptors.
To directly confirm that calmodulin is involved in GABAA
receptor-dependent inhibition of glutamate release, we tested
the effects of W7, a specific calmodulin inhibitor (55). Under
control conditions, glutamate release triggered by 1 mM 4AP
(26.8 0.7 nmol/mg/5min) was decreased to 21.4 0.8 nmol/
mg/5 min (79.9% of control) by muscimol (200 	M, Fig. 4D). In
the presence of W7 (20 	M), glutamate release was potently
inhibited to 16.7  1.7 nmol/mg/5 min (62.3% of control
release), but crucially, muscimol-induced inhibition of release
was abolished (17.9 1.6 nmol/mg/5min, 66.7%of control; Fig.
4D). However, in the presence of W5, an analogue of W7 with
10-fold lower affinity for calmodulin (56, 57), inhibition of the
control glutamate release (26.8 1.0 nmol/mg/5 min) by mus-
cimol (200 	M, 21.9  0.8 nmol/mg/5 min, 81.7% of control)
was unaffected (19.3 1.3 nmol/mg/5min, 82.8% ofW5 alone;
Fig. 4E). W5 caused a small but statistically insignificant inhi-
bition of glutamate release (23.3  1.1 nmol/mg/5 min, 86.9%
control; Fig. 4E). This comparison of the structurally similar
W7 andW5 indicates that it is themore potent anti-calmodulin
activity of the former that abrogates the GABAA receptor-me-
diated modulation of release. These results emphasize that
Ca2mediates the observed GABAA receptor-dependent inhi-
bition of glutamate release through the specific activation of
calmodulin.
Specificity of VGCCs Involved in the GABAA Receptor-medi-
ated Inhibition of Glutamate—Given that inhibition of gluta-
mate release by presynaptic GABAA receptor activity requires
an influx of Ca2 from the extracellular milieu, we applied
selective VGCC inhibitors to characterize the role of individual
Ca2 channel subtypes in this process. We started by investi-
gating the role of N-, P-, and Q-type VGCCs, which are known
to directly participate in triggering glutamate release from syn-
aptosomes (58, 59). To assess the role of P/Q-type VGCCs spe-
cifically, synaptosomes were preincubated with 100 	M -aga-
toxin IVA (-Aga IVA) (60). Glutamate release evoked by 1mM
4AP (25.6  0.8 nmol/mg/5 min; Fig. 5A) was significantly
decreased in the presence of-Aga IVAalone (17.2 1.5 nmol/
mg/5 min, 67.2% of control release, or muscimol alone (19.5
1.5 nmol/mg/5 min, 76.2% of control release). However, in the
presence of-Aga IVA, glutamate release was further inhibited
bymuscimol (12.1 1.6 nmol/mg/5min, 70.3%of release in the
presence of -Aga IVA alone; Fig. 5A). The additive relation-
ship between -Aga IVA and muscimol indicates that,
although P/Q-type VGCCs contribute significantly to 4AP-
evoked glutamate release, they appear not to mediate the mod-
ulatory effects of presynaptic GABAA receptors on glutamate
release.
To block N-type VGCCs specifically, synaptosomes were
preincubated with 10 	M -conotoxin GVIA (-CTx GVIA)
(61). Glutamate release evoked by 1 mM 4AP (25.6 0.9 nmol/
mg/5 min; Fig. 5B) under control conditions was significantly
decreased in the presence of -CTx GVIA alone (21.4  1.3
nmol/mg/5min, 84% of control) or muscimol alone (21.0 1.9
nmol/mg/5min, 82.1% of control). Crucially, in the presence of
-CTxGVIA, addition ofmuscimol caused a further inhibition
FIGURE 5. GABAA receptor-mediated inhibition of 4AP-evoked gluta-
mate release in thepresence of P/Q-, N-, or T-typeVGCCblockade. 4AP (1
mM)-evoked glutamate release from synaptosomes incubated in the pres-
ence of 1 mM CaCl2, and in the absence (black) or presence of-agatoxin IVA
(100	M, blue), muscimol (200	M, red), or both (green, n 7) (A);-conotoxin
GVIA (10 	M, blue), muscimol (200 	M, red), or both (green, n 4) (B); or NiCl2
(50 	M, in blue), muscimol (200 	M, red), or both (green, n  5) (C). Insets
compare the effects of P/Q-, N-, or T-type VGCC blockade (A–C, respectively)
on 4AP-evoked glutamate release (in blue), or the inhibition thereof by mus-
cimol (in green), as % control release 5 min after the addition of 4AP. Gluta-
mate release (mean  S.E., nmol/mg) values were calculated for every 2-s
time point, with the cumulative release 5 min after secretagogue (4AP) addi-
tion being used for statistical analysis. *, p  0.05 (one-way ANOVA with
post-hoc LSD test).
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of 4AP-evoked glutamate (17.1 1.4 nmol/mg/5min, 67.3% of
release in the presence of -CTx GVIA alone; Fig. 5B), indicat-
ing that the modulatory influence of GABAA receptor-medi-
ated inhibition of glutamate release is independent of N-type
Ca2 channel activity, even though, similarly to P/Q type
VGCCs, these channels are directly involved in mediating neu-
rotransmitter release.
A potential role of T-type VGCCs in GABAA receptor-me-
diated modulation was tested in the presence of NiCl2, which
selectively blocks these channels at the 50 	M concentration
used in our experiments (62, 63). Glutamate release evoked by 1
mM 4AP (24.5 0.5 nmol/mg/5 min) under control conditions
was unaffected byNiCl2 (22.3 1.8 nmol/mg/5min) indicating
that T-type VGCCs do not directly support glutamate release
from synaptosomes (Fig. 5C). Muscimol (200 	M) caused a sig-
nificant inhibition of glutamate release (18.7 1.9 nmol/mg/5
min, 76.3% of control release) as shown earlier, but notably the
modulation of glutamate release byGABAA receptor activation
was unaffected by the presence of NiCl2 (18.1 0.9 nmol/mg/5
min, 81.2% of NiCl2 release; Fig. 5C), indicating that T-type
VGCCs, similar to P/Q- andN-typeVGCCs, are not involved in
the observed modulation of glutamate release by presynaptic
GABAA receptors.
Next, the effect of inhibition of L-type VGCCs on the
observed muscimol-dependent inhibition of release was inves-
tigated in the presence of 1 	M nifedipine. Glutamate release
triggered by 1 mM 4AP (24.9  1.5 nmol/mg/5 min) under
control conditions was comparable with that obtained in the
presence of nifedipine (27.9  2.6 nmol/mg/5 min; Fig. 6A).
Importantly, although control release was significantly inhib-
ited by muscimol alone (200 	M, 19.2  1.1 nmol/mg/5 min,
77.1% of control), this effect of GABAA receptor activation was
abrogated in the presence of nifedipine, with release in pres-
ence of nifedipine and muscimol (25.0  1.5 nmol/mg/5 min;
Fig. 6A) being comparable with that in the presence of nifedip-
ine alone. Thus, although presynaptic L-type VGCCs are not
directly involved in triggering glutamate release (58, 59), their
activity appears critical for GABAA receptor-mediated inhibi-
tion of glutamate release.
Finally, the contribution of R-type VGCCs activity to
muscimol-dependent inhibition of glutamate releasewas inves-
tigated using SNX-482 (100 nM), a toxin shown to specifically
block 1E-subunit containing VGCCs at the concentration
used in our assays (64). Control glutamate release evoked by
4AP (25.2 1.7 nmol/mg/5 min) was reduced in the presence
of SNX-482 (22.3  1.1 nmol/mg/5 min, 88.5% of control
release), indicating that R-type VGCCs directly contribute to
release of glutamate from synaptosomes. Although 4AP-
evoked glutamate release was significantly reduced (20.4 1.4
nmol/mg/5min, 81% of control release) in the presence ofmus-
cimol alone (200 	M), this modulation was abolished by the
addition of SNX-482, with the releasemeasured in the presence
FIGURE 6. GABAA receptor-mediated inhibition of 4AP-evoked gluta-
mate release is abolished by L- or R-type VGCCs blockade. 4AP (1 mM)-
evokedglutamate release from synaptosomes incubated in the presence of 1
mM CaCl2 and in the absence (black) or presence of nifedipine (Nif) (1 	M,
blue), muscimol (M) (200 	M, red), or both (M/Nif) (green, n 4) (A); SNX-482
(100 nM, blue), muscimol (200	M, red), or both (green, n 6) (B). C,muscimol-
induced inhibition of 4AP-evoked glutamate release in R-type VGCC knock-
outmice. Synaptosomes fromwild-type (control, con,black, andmuscimol,M,
red) and R-type VGCC knock-out mice (control, 1E/, blue, and muscimol,
M/1E/, green) were incubated in the presence of 1 mM CaCl2, and in the
absence (con, 1E/) or presence of muscimol (200 	M,M,M/1E/) prior
to the addition of 1mM 4AP (n 5). Insets, A–C, respectively, compare effects
of nifedipine, SNX-482, or genetic ablation of the 1E-subunit supporting
R-type VGCC activity, on 4AP-evoked glutamate release (blue), or the inhibi-
tion thereof bymuscimol (green), as% control release 5min after the addition
of 4AP. Glutamate release (mean S.E., nmol/mg) values were calculated for
every 2-s time point, with the cumulative release 5 min after secretagogue
(4AP) addition being used for statistical analysis. *, p 0.05 (one-way ANOVA
with post-hoc LSD test).
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of SNX-482 and muscimol (22.9  1.1 nmol/mg/5 min) being
similar to that obtained in the presence of SNX-482 alone.
To authenticate the role of R-type VGCCs in the observed
modulation of glutamate release by muscimol, we carried out
experiments utilizing synaptosomes prepared from the neocor-
tex of1E subunit knock-out (1E/) mice lacking the R-type
VGCC activity (31). In wild-type mice, glutamate release
evoked by 1 mM 4AP under control conditions (35.5  1.3
nmol/mg/5 min) was significantly reduced by muscimol (200
	M, 31.6 0.4 nmol/mg/5 min, 89% of control release in wild-
type mice; Fig. 6C). Glutamate release triggered by 1 mM 4AP
was also significantly reduced inR-type knock-outmice (29.8
1.1 nmol/mg/5 min, 83.9% of the release in wild-type mice).
However, the inhibition of release by muscimol observed in
wild-type synaptosomes was completely abolished in synapto-
somes isolated from R-type VGCC knock-out mice, with the
release measured in the presence of muscimol (29.1  1.3
nmol/mg/5 min) being similar to that in the absence of musci-
mol (Fig. 6C). Together, these experiments demonstrate a key
role of R-type VGCCs as mediators of the presynaptic GABAA
receptor-mediated regulation of glutamate release.
DISCUSSION
The data presented here reveal the presence and examine the
function of presynaptic GABAA receptors in a population of
glutamatergic nerve terminals in the adult rat neocortex. We
demonstrate that nerve terminal GABAA receptors activate
presynaptic Ca2/calmodulin-dependent signaling to inhibit
depolarization (4AP)-evokedCa2 influx and glutamate release
from isolated nerve terminals. This inhibitory action is depend-
ent on the activity of the NKCC1 transporter, Ca2 and cal-
modulin, and the activity of L- and/or R-typeVGCCs.Although
both L- and/or R-type VGCC appear essential for modulation,
they evidently play distinctive roles in this process given that, of
the two, only R-type channels contribute directly to the release
of glutamate.
We initially defined the presynaptic effects of GABAA recep-
tors using Ca2/calmodulin-dependent phosphorylation of
synapsin I, as a direct and sensitive biochemical readout of
alterations in intraterminal [Ca2]i (43, 65). The synapsin fam-
ily of small synaptic vesicle-associated proteins is ubiquitous
throughout the central nervous system but is exclusively local-
ized to presynaptic nerve terminals (66). With this definitive
presynaptic marker, we demonstrate that GABAA receptor
activity increases basal intraterminal [Ca2]i, as reflected by
increased CaMKII-dependent phosphorylation of synapsin I,
whereas their inhibition produces a decrease in this parameter.
Moreover, our immunohistochemical analysis to delineate this
signaling revealed its exclusive localization to a subpopulation
of glutamatergic terminals and its notable absence from
GABAergic terminals, the latter finding being in agreement
with the absence of Ca2/calmodulin-dependent kinases and
phosphatases at GABAergic synapses (67, 68). Crucially, this
analysis evinces GABAA receptors as modulatory heterorecep-
tors on20% of glutamatergic terminals in the rat neocortex.
The observed changes in intraterminal [Ca2]i suggest that
nerve terminalGABAA receptors effect presynaptic depolariza-
tion rather than the hyperpolarization that is typical of postsyn-
aptically localized receptors (1). The functional outcome of
GABAA receptor activation is predominantly determined by
the Cl electrochemical gradient established across the plasma
membrane. This is in turn regulated by the activity of cation/
chloride cotransporters such as KCC2, which extrudes Cl,
and/or NKCC1, which transports Cl into the cytosol (1).
Whereas KCC2 is absent from presynaptic nerve terminals
(69), NKCC1 has been implicated in the regulation of intrater-
minal [Cl] (49, 50), to achieve the high levels of 20–22mM (cf.
somatodendritic compartment), directly measured in the calyx
of Held (70), pituitary terminals (71), and retinal bipolar cell
terminals (72). In experiments reported herein, the inhibition
of glutamate release by GABAA receptor agonists was highly
sensitive to blockade of the cation/chloride cotransporter
NKCC1. Together, the data suggest that high intraterminal
[Cl]i, leading to the depolarization of nerve terminals by
GABAA receptors, is of critical importance for the regulation of
glutamate release by these receptors.
Whereas depolarizing effects of presynaptic GABAA recep-
tors have been supported by electrophysiological evidence (1,
9), the final functional outcome of their activity at the level of
neurotransmitter release has been contentious given the con-
flicting reports indicating both stimulation and inhibition of
release being mediated by GABAA receptors (9). As described
here, inhibition of the evoked release by nerve terminal GABAA
receptors has also been observed in the spinal cord (73), frontal
cortex (74), hippocampus (20, 75), suprachiasmatic nucleus
(76), ventromedial hypothalamus (49), posterior pituitary (71,
77), etc. Conversely, stimulation of spontaneous and evoked
release of neurotransmitter by presynaptic GABAA receptors
has been described in the cerebellum (18, 19), hippocampus
(21–25), auditory brainstem (27), locus ceruleus (50), ventral
tegmental area (28), etc. Typically, facilitation is largely
observed in tissue from young animals. In addition to factors
such as the age of animals, it is apparent that the type of nerve
terminal or the central nervous system region determines the
final functional outcome of GABAA receptor activity. This
would be determined by the repertoire of presynaptically
expressed GABAA receptor subtypes, as well as the operative
signaling pathways and their targets (including voltage-gated
ion channels such as VGCCs modulated to regulate basal as
well as evoked intraterminal [Ca2]i; see our biochemical
experiments and Ref. 26).
We demonstrate that an increase in basal intraterminal
[Ca2]i resulting from GABAA receptor activity is an obligate
requirement for subsequent inhibition of depolarization (4AP)-
evokedCa2 influx and glutamate release, i.e. themodulation of
release is absent in the absence of extracellular Ca2 or in the
presence of extracellular Ba2. Interestingly, when ionomycin
was used as the secretagogue after GABAA receptor activation,
no modulation was observed. These data indicate that GABAA
receptor- and Ca2-dependent regulation of VGCC activity
underpins the subsequent regulation of excitation-secretion
coupling.
We elucidated the VGCC subtype(s) involved in the GABAA
receptor invoked regulatory pathway by monitoring its sensi-
tivity to VGCC subtype-specific antagonists added during the
activation ofGABAA receptors. Although blockade of P/Q-type
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(by -Aga IVA) or N-type (by -CTxGVIA) VGCCs reduces
4AP-evoked release substantially, conspicuously, the residual
release in each case is still inhibited by GABAA receptor activa-
tion with muscimol. T-type VGCC block (by NiCl2) had no
effect on evoked release or the inhibition thereof by prior mus-
cimol treatment.
In contrast, L-type VGCC block by nifedipine abolished the
inhibition of glutamate release produced by muscimol (note
nifedipine has no effect on glutamate release in control condi-
tions). Although L-type VGCCs are mainly located at the soma
and dendrites (78), Ca2 influx through these channels during
repetitive stimulation has been implicated in regulation of
GABA release from cultured GABAergic neurons, presumably
through a presynaptic localization and operation (79). More
directly, L-type VGCCs also appear to be present inmossy fiber
terminals where they mediate large Ca2 currents (80). It is
therefore feasible that depolarizing action of nerve terminal
GABAA receptors initiates a long lasting Ca2-dependent reg-
ulatory mechanism following L-type VGCC activation.
Finally, we examined the role of R-type VGCCs in the
observed regulation using both pharmacological blockade by
SNX-482, and by the genetic ablation of the 1E channel sub-
unit in mice (31). In both these models, the inhibition of glu-
tamate release by muscimol was abolished. Thus, together
with L-type VGCCs, R-type VGCCs are implicated in the
modulation of release produced by presynaptic GABAA
receptor activation.
A key question arising is: what is the Ca2-dependent mech-
anism invoked by presynaptic GABAA receptors to inhibit glu-
tamate release? Our observations that GABAA receptor-
dependent inhibition of release is ablated by the inhibitor W7,
but unaffected by its inactive analogue W5, clearly implicates
calmodulin as a modulatory player. The effects of Ca2/cal-
modulin on the observed regulation could operate at any num-
ber of loci in the release cascade. Judging from the lack of
GABAA receptor-mediated regulation of release when ionomy-
cin is used as the secretagogue, involvement of targets down-
stream of Ca2 entry is obviated. This leaves potential regula-
tion at the level of Ca2 entry or upstream at loci controlling
nerve terminal excitability.
Direct inhibitory action of GABAA receptor-mediated Ca2
entry onVGCCs themselves is a tenable possibility given that all
the high threshold VGCCs have been shown to be subject to
Ca2/calmodulin-dependent inactivation (CDI) (81–85). If
VGCCs are indeed direct targets for GABAA receptor-medi-
ated inhibition, R-type VGCCs surface as the only feasible tar-
gets given our data showing that P/Q- andN-typeVGCCblock-
ade is of no consequence to the regulation seen, and L-type
VGCCs do not support release. These observations not only
support R-type VGCCs as key players in the regulation seen,
but they obviate the possibility that GABAA receptor-depend-
ent regulation impinges upstream at the level of channels reg-
ulating nerve terminal excitability, as such an actionwould then
be predicted to equally affect all release-supporting VGCCs.
There are increasing examples of R-type VGCCs supporting
neurotransmitter release in the calyx of Held (86), glutamater-
gic transmission in the rat hippocampus (87) and in oxytocin
secretion in neurohypophysial terminals (88). Our data with
1E-subunit knock-out mice now show that there is significant
support of glutamate release by these VGCCs. The question as
to whether direct CDI of R-type VGCCs underlies the GABAA
receptor-mediated inhibition ismore open.This is becauseCDI
is generally short lived, yet the regulation of release by musci-
mol is long lasting because it evidently occurs/persists for some
time after initiation of Ca2/calmodulin-dependent signaling.
Moreover, CDI per se would also invoke P/Q- and N-type
VGCCs in the regulation, whichwe observe clearly not to be the
case. An alternative possibility is that the Ca2/calmodulin-de-
pendent regulation impinges on R-type VGCC activity indi-
rectly, by mediating activation of a phosphorylation or dephos-
phorylation cascade. Interestingly in this regard, in the
dendritic spines of the CA1 pyramidal cells, L-type VGCC-me-
diated elevations of Ca2 are suggested to activate CaMKII
(and/or Ca2-dependent adenylyl cyclase), which then leads to
a relatively long lived depression of R-type VGCCs (89). Simi-
larly, in GABAergic terminals projecting to Meynert neurones,
L- and R-type VGCCs collaborate in mediating spontaneous
and evoked neurotransmitter release, respectively (90). A
tenable hypothesis arising from the present data would be
that GABAA receptor-mediated depolarization leads to
presynaptic L-type VGCC-mediated activation of Ca2/
calmodulin-dependent signaling, which subsequently effects
depression of Ca2 entry through R-type VGCCs during the
release of glutamate. This hypothesis is consistent with the
abolition of GABAA receptor-mediated inhibition of gluta-
mate release following the pharmacological block of L- or
R-type VGCCs, or deletion of the 1E-subunit underpinning
R-type Ca2 conductance.
Together, our results demonstrate that nerve terminal
GABAA receptors play an important and specific role in the
regulation of glutamate release from a population of glutama-
tergic nerve terminals in the neocortex. ThusGABAA receptors
may instigate a powerful activity-dependent presynaptic con-
trol of excitatory synapses, and as such, they represent a novel
functional target for a plethora of GABAergic pharmacological
agents.
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